Amendments to the Claims

Cancel claims 1-34 and insert new claims 35-59 as shown below.

Claims 1-34 (Cancelled)

Claim 35. A compound of Formula I



II

wherein each of R^1, R^2, and R^3 is independently selected from hydrido, alkyl, aralkyl, halo, alkoxy, cyano, nitro, amino, alkylamino, N-acylamino, alkylsulfonyloxy, aminosulfonyl, N-(haloalkylcarbonyl)amino, peptidyl, amino acid residue,



wherein R^5 is a monocyclic or bicyclic ring system containing a 5-membered heterocycle consisting of one N and four carbon atoms, a monocyclic or bicyclic ring system containing a 5-membered heterocycle consisting of one O and four carbon atoms, and a six-membered heterocycyl consisting of one N and four C atoms, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of alkyl, alkoxy, aryloxy, alkylthio, arylthio, halo, nitro, N-acylamino, amino, alkylamino, alkoxycarbonyl, amino acid residue and peptidyl;

wherein R^6 is selected from the group consisting of alkyl, aryl, aralkyl, heterocyclyl and heterocyclylalkyl, wherein R^6 is optionally substituted at a substitutable position with a radical selected from the group consisting of alkoxy,

aryloxy, alkylthio, arylthio, halo, nitro, N-acylamino, amino, alkylamino and alkoxycarbonyl;

wherein Y is selected from fluoroalkyl and



;

wherein Q is selected from the group consisting of alkoxy, aryloxy, aralkyloxy, amino acid residue, peptidyl, and -NHR^7; and

wherein R^7 is a radical selected from the group consisting of alkyl, aralkyl, and heterocyclylalkyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from amino, nitrogen-containing heterocyclyl and alkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 36 (New) The compound of Claim 35 wherein each of R^1, R^2, and R^3 is independently selected from the group consisting of hydrido, lower alkyl, lower aralkyl, halo, lower alkoxy, cyano, nitro, amino, lower alkylamino, N-acylamino, lower alkylsulfonyloxy, aminosulfonyl, lower N-(haloalkylcarbonyl)amino, amino acid residue, peptidyl,





, and



;

wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue and peptidyl; wherein R^6 is selected from the group consisting of lower alkyl, 6-10-membered aryl, lower aralkyl, 5-10-membered heterocyclyl and lower heterocyclylalkyl, wherein R^6 is

optionally substituted at a substitutable position with a radical selected from lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, and lower alkoxycarbonyl; wherein Y is selected from lower fluoroalkyl and



;

wherein Q is selected from the group consisting of lower alkoxy, phenyloxy, lower aralkyloxy, N-amino acid residue, N-peptidyl, and -NHR^7; and wherein R^7 is a radical selected from the group consisting of lower alkyl, lower aralkyl, and lower heterocyclylalkyl, wherein R^7 is optionally substituted at a substitutable position with one or more radical selected from the group consisting of amino, 5-6-membered nitrogen-containing heterocyclyl and lower N,N-dialkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 37 (New) Compound of Claim 36 wherein Y is lower fluoroalkyl; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, lower alkyl, halo, lower alkoxy, nitro, and amino; and wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue, and peptidyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 38 (New) Compound of Claim 37 wherein Y is selected from the group consisting of difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, 1,1-difluoroethyl, and 1,1-difluoropropyl; wherein each of R^1, R^2 and R^3 is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy,

nitro, and amino; wherein R^5 is selected from the group consisting of furyl, pyrrolyl, benzofuranyl, indolyl, and pyridyl, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, phenyloxy, methylthio, phenylthio, fluoro, chloro, bromo, iodo, nitro, N-formylamino, acetylamino, amino, N,N-dimethylamino and methoxycarbonyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 39 (New) Compound of Claim 36 wherein Y is



;

wherein Q is selected from lower alkoxy, phenyloxy, lower aralkyloxy, N-amino acid residue, N-peptidyl, and $-NHR^7$; and wherein R^7 is a radical selected from the group consisting of lower alkyl, lower aralkyl, and lower heteroaralkyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from amino, 5-6 membered nitrogen-containing heterocyclyl and lower N,N-dialkylamino; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, lower alkyl, halo, lower alkoxy, nitro, and amino; and wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue, and peptidyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 40 (New) Compound of Claim 39 wherein Y is



;

wherein Q is selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, phenyloxy, benzyloxy, phenylethoxy, and -NHR^7; and wherein R^7 is a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, benzyl, phenethyl, oxazolylmethyl, oxazolylethyl, imidazolylmethyl, imidazolylethyl, oxazolinylmethyl, oxazolinylethyl, indolylethyl, indolylmethyl, pyridylmethyl, thienylmethyl, and furylethyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from the group consisting of amino, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, pyridyl, pyrimidyl and N,N-dimethylamino; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, nitro, and amino; and wherein R^5 is selected from the group consisting of furyl, pyrrolyl, benzofuranyl, indolyl, and pyridyl, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, *tert*-butoxy, phenyloxy, methylthio, phenylthio, fluoro, chloro, bromo, iodo, nitro, N-formylamino, N-acetylamino, amino, N,N-dimethylamino and methoxycarbonyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 41 (New) A pharmaceutical composition comprising a therapeutically-effective amount of a compound and a pharmaceutically-acceptable carrier or diluent, said compound selected from a compound of Formula I



II

wherein each of R^1, R^2 and R^3 is independently selected from hydrido, alkyl, aralkyl, halo, alkoxy, cyano, nitro, amino, alkylamino, N-acylamino,

alkylsulfonyloxy, aminosulfonyl, N-(haloalkylcarbonyl)amino, peptidyl, amino acid residue,



wherein R^5 is selected from a monocyclic or bicyclic ring system containing a 5-membered heterocyclyl consisting of one N and four carbon atoms, a monocyclic or bicyclic ring system containing a 5-membered heterocyclyl consisting of one O and four carbon atoms, and a six-membered heterocycyl consisting of one N and four C atoms, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of alkyl, alkoxy, aryloxy, alkylthio, arylthio, halo, nitro, N-acylamino, amino, alkylamino, alkoxycarbonyl, amino acid residue and peptidyl;

wherein R^6 is selected from alkyl, aryl, aralkyl, heterocyclyl and heterocyclylalkyl, wherein R^6 is optionally substituted at a substitutable position with a radical selected from the group consisting of alkoxy, aryloxy, alkylthio, arylthio, halo, nitro, N-acylamino, amino, alkylamino and alkoxycarbonyl;

wherein Y is selected from fluoroalkyl and



;

wherein Q is selected from the group consisting of alkoxy, aryloxy, aralkyloxy, amino acid residue, peptidyl, and $-NHR^7$; and

wherein R^7 is a radical selected from alkyl, aralkyl, and heterocyclylalkyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from the group consisting of amino, nitrogen-containing heterocyclyl and alkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 42 (New) A pharmaceutical composition of Claim 41 wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, lower alkyl, lower aralkyl, halo, lower alkoxy, cyano, nitro, amino, lower alkylamino, N-acylamino, lower alkylsulfonyloxy, aminosulfonyl, lower N-(haloalkylcarbonyl)amino, amino acid residue, peptidyl,


,

,

,

, and

;

wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue and peptidyl; wherein R^6 is selected from the group consisting of lower alkyl, 6-10-membered aryl, lower aralkyl, 5-10-membered heterocyclyl and lower heterocyclylalkyl, wherein R^6 is optionally substituted at a substitutable position with a radical selected from the group consisting of lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, and lower alkoxycarbonyl; wherein Y is selected from lower fluoroalkyl and


;

wherein Q is selected from lower alkoxy, phenyloxy, lower aralkyloxy, N-amino acid residue, N-peptidyl, and $-NHR^7$; and wherein R^7 is a radical selected from lower alkyl, lower aralkyl, and lower heterocyclylalkyl, wherein R^7 is optionally substituted at a substitutable position with one or more radical selected from amino, 5-6-membered nitrogen-containing heterocyclyl and lower N,N-dialkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 43 (New) A pharmaceutical composition of Claim 42 wherein Y is lower fluoroalkyl; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, lower alkyl, halo, lower alkoxy, nitro, and amino; and wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue, and peptidyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 44 (New) A pharmaceutical composition of Claim 43 wherein Y is selected from the group consisting of difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, 1,1-difluoroethyl, and 1,1-difluoropropyl; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, nitro, and amino; wherein R^5 is selected from the group consisting of furyl, benzofuranyl, indolyl, and pyridyl, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, phenyloxy, methylthio, phenylthio, fluoro, chloro, bromo, iodo, nitro, N-formylamino, acetylamino, amino, N,N-dimethylamino and methoxycarbonyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 45 (New) A pharmaceutical composition of Claim 42 wherein Y is



;

wherein Q is selected from the group consisting of lower alkoxy, phenyloxy, lower aralkyloxy, N-amino acid residue, N-peptidyl, and -NHR^7; and wherein R^7 is a radical

selected from lower alkyl, lower aralkyl, and lower heteroaralkyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from the group consisting of amino, 5-6 membered nitrogen-containing heterocyclyl and lower N,N-dialkylamino; wherein each of R^1, $R^2$and R^3 is independently selected from the group consisting of hydrido, lower alkyl, halo, lower alkoxy, nitro, and amino; and wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue, and peptidyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 46 (New) A pharmaceutical composition of Claim 45 wherein Y is



;

wherein Q is selected from methoxy, ethoxy, propoxy, isopropoxy, butoxy, phenyloxy, benzyloxy, phenylethoxy, and -NHR^7; and wherein R^7 is a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, benzyl, phenethyl, oxazolylmethyl, oxazolylethyl, imidazolylmethyl, imidazolylethyl, oxazolinylmethyl, oxazolinylethyl, indolylethyl, indolylmethyl, pyridylmethyl, thienylmethyl, and furylethyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from amino, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, pyridyl, pyrimidyl and N,N-dimethylamino; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, nitro, and amino; and wherein R^5 is selected from furyl, pyrrolyl, benzofuranyl, indolyl, and pyridyl, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, methoxy, ethoxy, propoxy,

isopropoxy, butoxy, *tert*-butoxy, *tert*-butoxy, phenyloxy, methylthio, phenylthio, fluoro, chloro, bromo, iodo, nitro, N-formylamino, N-acetylamino, amino, N,N-dimethylamino and methoxycarbonyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 47 (New) A method of treating herpes viral infection in a subject, said method comprising treating said subject with an effective amount of a compound of Formula I



II

wherein each of R^1, R^2 and R^3 is independently selected from hydrido, alkyl, aralkyl, halo, alkoxy, cyano, nitro, amino, alkylamino, N-acylamino, alkylsulfonyloxy, aminosulfonyl, N-(haloalkylcarbonyl)amino, peptidyl, amino acid residue,



wherein R^5 is selected from the group consisting of a monocyclic or bicyclic ring system containing a 5-membered heterocyclyl heterocyclyl-consisting of one N and four carbon atoms, a monocyclic or bicyclic ring system containing a 5-membered heterocyclyl consisting of one O and four carbon atoms, and a six-membered heterocycyl consisting of one N and four C atoms, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of alkyl, alkoxy, aryloxy, alkylthio, arylthio, halo, nitro, N-acylamino, amino, alkylamino, alkoxycarbonyl, amino acid residue and peptidyl;

wherein R^6 is selected from alkyl, aryl, aralkyl, heterocyclyl and heterocyclylalkyl, wherein R^6 is optionally substituted at a substitutable position with a radical selected from the group consisting of alkoxy, aryloxy, alkylthio, arylthio, halo, nitro, N-acylamino, amino, alkylamino and alkoxycarbonyl;

wherein Y is selected from fluoroalkyl and



;

wherein Q is selected from the group consisting of alkoxy, aryloxy, aralkyloxy, amino acid residue, peptidyl, and -NHR^7; and

wherein R^7 is a radical selected from alkyl, aralkyl, and heterocyclylalkyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from the group consisting of amino, nitrogen-containing heterocyclyl and alkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 48 (New) A method of Claim 47 wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, lower alkyl, lower aralkyl, halo, lower alkoxy, cyano, nitro, amino, lower alkylamino, N-acylamino, lower alkylsulfonyloxy, aminosulfonyl, lower N-(haloalkylcarbonyl)amino, amino acid residue, peptidyl,





wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue and peptidyl; wherein R^6 is selected from the group consisting of lower alkyl, 6-10-membered aryl, lower aralkyl, 5-10-

membered heterocyclyl and lower heterocyclylalkyl, wherein R^6 is optionally substituted at a substitutable position with a radical selected from the group consisting of lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, and lower alkoxycarbonyl; wherein Y is selected from lower fluoroalkyl and



;

wherein Q is selected from the group consisting of lower alkoxy, phenyloxy, lower aralkyloxy, N-amino acid residue, N-peptidyl, and -NHR^7; and wherein R^7 is a radical selected from lower alkyl, lower aralkyl, and lower heterocyclylalkyl, wherein R^7 is optionally substituted at a substitutable position with one or more radical selected from the group consisting of amino, 5-6-membered nitrogen-containing heterocyclyl and lower N,N-dialkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 49 (New) A method of Claim 48 wherein Y is lower fluoroalkyl; wherein each of R^1, R^2 and R^3 is independently selected from hydrido, lower alkyl, halo, lower alkoxy, nitro, and amino; and wherein R^5 is optionally substituted at a substitutable position of a phenyl or heteroaryl radical with one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue, and peptidyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 50 (New) A method of Claim 49 wherein Y is selected from difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, 1,1-difluoroethyl, and 1,1-difluoropropyl; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, nitro, and amino; wherein R^5 is selected from the group consisting of

furyl, pyrrolyl, benzofuranyl, indolyl, and pyridyl, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, phenyloxy, methylthio, phenylthio, fluoro, chloro, bromo, iodo, nitro, N-formylamino, acetylamino, amino, N,N-dimethylamino and methoxycarbonyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 51 (New) A method of Claim 47 wherein Y is



;

wherein Q is selected from the group consisting of lower alkoxy, phenyloxy, lower aralkyloxy, N-amino acid residue, N-peptidyl, and -NHR^7; and wherein R^7 is a radical selected from lower alkyl, lower aralkyl, and lower heteroaralkyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from the group consisting of amino, 5-6 membered nitrogen-containing heterocyclyl and lower N,N-dialkylamino; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, lower alkyl, halo, lower alkoxy, nitro, and amino; and wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, phenyloxy, lower alkylthio, phenylthio, halo, nitro, N-acylamino, amino, lower alkylamino, lower alkoxycarbonyl, amino acid residue, and peptidyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 52 (New) A method of Claim 51 wherein Y is



;

wherein Q is selected from the group consisting of methoxy, ethoxy, propoxy, isopropoxy, butoxy, phenyloxy, benzyloxy, phenylethoxy, and -NHR^7; and wherein R^7 is a radical selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, benzyl, phenethyl, oxazolylmethyl, oxazolylethyl, imidazolylmethyl, imidazolylethyl, oxazolinylmethyl, oxazolinylethyl, indolylethyl, indolylmethyl, pyridylmethyl, thienylmethyl, and furylethyl, wherein R^7 is optionally substituted at a substitutable position with a radical selected from the group consisting of amino, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, pyridyl, pyrimidyl and N,N-dimethylamino; wherein each of R^1, R^2 and R^3 is independently selected from the group consisting of hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, nitro, and amino; and wherein R^5 is selected from the group consisting of furyl, pyrrolyl, benzofuranyl, indolyl, and pyridyl, wherein R^5 is optionally substituted at a substitutable position with one or more substituents selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, *tert*-butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, *tert*-butoxy, *tert*-butoxy, phenyloxy, methylthio, phenylthio, fluoro, chloro, bromo, iodo, nitro, N-formylamino, N-acetylamino, amino, N,N-dimethylamino and methoxycarbonyl; or a pharmaceutically-acceptable salt or tautomer thereof.

Claim 53 (New) The method of Claim 47 wherein the subject is infected with a herpesvirus selected from the group consisting of herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella-zoster virus (VSV), Epstein-Barr virus, herpesvirus-6 (HHV-6), herpesvirus-7 (HHV-7), herpesvirus-8 (HHV-8), psuedorabies and rhinotracheitis.

Claim 54 (New) A method of inhibiting a viral protease, said method comprising treating said subject with an effective amount of a compound of Claim 35.

Claim 55 (New) The method of Claim 54, wherein the viral protease is a herpesvirus protease.

Claim 56 (New) The method of Claim 55 wherein the viral protease is selected from the group consisting of a CMV protease, an HSV-1 protease and a HSV-2 protease.

Claim 57 (New) The method of Claim 56 wherein the viral protease is a CMV protease, encoded by U_L80.

Claim 58 (New) A method of prophylactic treatment of herpes viral infection in a subject, said method comprising treating said subject with an effective amount of a compound of Claim 35.

Claim 59 (New) The method of Claim 58 wherein the herpesvirus is selected from the group consisting of herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella-zoster virus (VSV), Epstein-Barr virus, herpesvirus-6 (HHV-6), herpesvirus-7 (HHV-7), herpesvirus-8 (HHV-8), psuedorabies and rhinotracheitis.